Align Technology (0HCK.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0HCK.L in your mock portfolio yet.
With EPS of 8.88 and a PE ratio of 18.57, Align Technology is currently profitable and valued at a discount to its own historical growth profile and many high‑growth medtech peers. However, the sharp disconnect between the current stock price and the 200‑day moving average implies that the market is discounting slower growth, margin pressure, or elevated execution risk. Without more recent revenue and margin data, the earnings profile looks solid but not strong enough to offset current market concerns.
The stock is trading at $165.00, down 12.4% in the last month and far below its 200‑day moving average of $293.63, signaling a strong downtrend. An RSI of 37.47 is below neutral but not yet deeply oversold, indicating persistent selling pressure with only modest signs of potential technical support. Overall, the technical picture is weak and suggests negative sentiment and elevated downside risk in the near term.
Alternative data points show softening demand and engagement signals: app downloads are down sharply month over month, and job openings are also declining. Social media follower growth is minimal across most platforms, suggesting limited incremental brand momentum or marketing reach at present. While web traffic remains sizable, the broader set of signals leans toward cooling growth rather than acceleration.
Align Technology remains profitable with a reasonable valuation multiple, but the stock’s sharp decline, deep discount to its 200‑day moving average, and weakening alternative data signals point to a challenging near‑term setup. The combination of negative price momentum, cooling app and hiring trends, and only modest engagement growth suggests that investor sentiment is likely to stay cautious. Overall, the risk‑reward profile appears skewed to the downside in the short term, with any bullish case depending on a clear re‑acceleration in fundamentals that is not yet evident in the data provided.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started